CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
Active, not recruiting · NCT06973096 · Registry updated 2026-07-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-07-22 | NCT06973096 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Kite Pharma (a Gilead Company) | 2 |
| University of Pennsylvania | 502 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Pennsylvania | Philadelphia | United States | 507 |